CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.

Purpose: CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as a cancer immunotherapeutic but development has been hampered by on-target off-tumor toxicities. A CD137 agonist targeted to the prostate-specific membrane antigen (PSMA), frequently and highly expressed on castration-resistant metastatic prostate cancer (mCRPC) tumor cells, could bring effective immunotherapy to this immunologically challenging to address disease.

Evaluation of , a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial.

The thromboxane receptor (TP) antagonist is in clinical development for treatment of cardiopulmonary diseases, such as pulmonary arterial hypertension. In this randomized, placebo-controlled Phase I clinical trial, , administered as the oral formulation , was evaluated for safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy males. The first-in-human trial had three Parts: A, single ascending dose (SAD) study with seven groups given 0.

Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration.

Caffeine promotes hyperthermia and lethality when co-administered with the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") to rats. In the present study, co-administration of caffeine (10 mg/kg, s.c.

Adenosine A1 receptor blockade mimics caffeine's attenuation of ethanol-induced motor incoordination.

The effects of co-administration of caffeine and ethanol were assessed on the motor coordination of rats on the accelerating rotarod (accelerod). Ethanol (2.5 g/kg, orally) decreased motor performance on the accelerod.

Protective effects of vanoxeamine (GBR 12909) against ischaemia-induced hyperactivity and neurodegeneration in the gerbil model of cerebral ischaemia.

In Mongolian gerbils, bilateral carotid occlusion (BCO) followed by reperfusion causes uniform destruction of the CA1 pyramidal neurons in the hippocampus, and this damage correlates with an increase in locomotor activity. Various drugs, such as NMDA antagonists, calcium channel blockers, and free radical scavengers, have provided neuroprotection against ischaemia-induced damage. More recently, the neuroprotective effects of dopamine have been investigated.